RARE vs BIIB Comparison: AI Score, Valuation, Performance and Upside
Compare Ultragenyx and Biogen by rare disease pipeline breadth, commercialization risk, platform technology (gene vs antibody), pathway to profitability, and which biotech offers better near-term catalysts.
Use this Ultragenyx vs Biogen comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
RARE and BIIB are closely matched — they split the tracked metrics evenly. BIIB has delivered stronger 1-year price return (+52.95% vs -8.82%), though RARE has the better forward P/E setup (8.01x vs 12.25x for BIIB). Analyst consensus implies meaningfully more upside for RARE (+113.30%) than for BIIB (+15.47%).
| Metric | RARE | BIIB |
|---|---|---|
| AI score | 25.1 | 28.7 |
| AI rank | #2853 | #2349 |
| Latest close | $24.91 | $201.82 |
| 1M return | -23.07% | -6.62% |
| 6M return | +2.64% | +12.69% |
| 1Y return | -8.82% | +52.95% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RARE | BIIB |
|---|---|---|
| 1Y ago | $9.12K (-8.8%) started 2025-07-31 | $15.27K (+52.7%) started 2025-08-04 |
| 5Y ago | $3.08K (-69.2%) started 2021-08-02 | $6K (-40.0%) started 2021-08-05 |
| 10Y ago | $3.92K (-60.8%) started 2016-08-01 | $6.39K (-36.1%) started 2016-08-05 |
Hypothetical — past performance does not guarantee future results.
| Metric | RARE | BIIB |
|---|---|---|
| Market cap | $2.46B | $29.99B |
| Trailing P/E | N/A | 36.11 |
| Forward P/E | 8.01 | 12.25 |
| Price/Sales | 3.68 | 1.99 |
| EV/Revenue | 4.85 | 3.69 |
| Analyst target | $53.37 | $234.35 |
| Target upside | +113.30% | +15.47% |
| Metric | RARE | BIIB |
|---|---|---|
| Revenue growth | -2.20% | 3.40% |
| Earnings growth | N/A | -84.80% |
| EPS growth | N/A | -84.80% |
| FCF margin | -32.70% | +12.63% |
| Operating margin | N/A | 25.06% |
| Profit margin | -90.90% | 8.32% |
| ROIC proxy | N/A | 4.58% |
| Return on equity | N/A | 4.58% |
| Dividend yield | 0.00% | N/A |
| Beta | 0.31 | 0.16 |
| Debt/equity | N/A | 44.33 |
| Current ratio | 2.02 | 1.86 |
| Quick ratio | 1.65 | 0.94 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RARE | BIIB |
|---|---|---|---|
| 1Y | Growth | -8.82% | +52.66% |
| CAGR | -8.83% | +52.80% | |
| Sharpe ratio | 0.18 | 1.24 | |
| Max drawdown | 49.37% | 14.34% | |
| Max daily drop | 42.32% | 8.17% | |
| Max wkly drop | 41.13% | 12.37% | |
| 5Y | Growth | -69.19% | -40.04% |
| CAGR | -21.00% | -9.73% | |
| Sharpe ratio | -0.23 | -0.26 | |
| Max drawdown | 81.93% | 67.59% | |
| Max daily drop | 42.32% | 8.17% | |
| Max wkly drop | 41.13% | 13.62% | |
| 10Y | Growth | -60.79% | -36.12% |
| CAGR | -8.94% | -4.39% | |
| Sharpe ratio | 0.03 | -0.02 | |
| Max drawdown | 89.57% | 72.66% | |
| Max daily drop | 42.32% | 29.23% | |
| Max wkly drop | 41.13% | 34.30% |
| Category | RARE | BIIB |
|---|---|---|
| Company | RARE | BIIB |
| Sector | N/A | Healthcare |
| Industry | N/A | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.